Literature DB >> 26077355

Testosterone Replacement Therapy on the Natural History of Prostate Disease.

Aaron Moore1, Michael J Butcher, Tobias S Köhler.   

Abstract

The physiology of testosterone production and action are closely related to prostatic disease. An understanding of the natural history of testosterone and prostate growth and development is needed in order to understand this complex relationship. Lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), prostate cancer, and sexual function are common disorders for which testosterone is thought to play a role. Proposed in this review are some theories as to how testosterone interacts to potentially ameliorate these conditions. Further research is needed, but we feel our proposed points are valid given the review of the literature.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26077355     DOI: 10.1007/s11934-015-0526-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  85 in total

1.  Endocrine changes with prostatic carcinoma.

Authors:  S C SOMMERS
Journal:  Cancer       Date:  1957 Mar-Apr       Impact factor: 6.860

2.  Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume.

Authors:  A V Pechersky; V I Mazurov; V F Semiglazov; A I Karpischenko; V V Mikhailichenko; A V Udintsev
Journal:  Int J Androl       Date:  2002-04

3.  Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Authors:  Stephanie T Page; Lianne Hirano; Janet Gilchriest; Manjiri Dighe; John K Amory; Brett T Marck; Alvin M Matsumoto
Journal:  J Urol       Date:  2011-05-14       Impact factor: 7.450

4.  Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.

Authors:  Stephanie T Page; Daniel W Lin; Elahe A Mostaghel; Brett T Marck; Jonathan L Wright; Jennifer Wu; John K Amory; Peter S Nelson; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2010-12-22       Impact factor: 5.958

Review 5.  Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.

Authors:  Tim M van der Sluis; André N Vis; R Jeroen A van Moorselaar; Hong N Bui; Marinus A Blankenstein; Eric J H Meuleman; Annemieke C Heijboer
Journal:  BJU Int       Date:  2011-10-12       Impact factor: 5.588

6.  Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly men.

Authors:  Ozan Bozkurt; Deniz Bolat; Omer Demir; Oktay Ucer; Ali Sahin; Burak Ozcift; Abdulkadir Pektaş; Tahir Turan; Bilal H Gümüş; Ertan Can; Ahmet Bolukbasi; Haluk Erol; Adil Esen
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

7.  Serum sex hormones and measures of benign prostatic hyperplasia.

Authors:  Rosebud O Roberts; Debra J Jacobson; Thomas Rhodes; George G Klee; Michael M Leiber; Steven J Jacobsen
Journal:  Prostate       Date:  2004-10-01       Impact factor: 4.104

8.  Prevalence of androgen deficiency in men with erectile dysfunction.

Authors:  Tobias S Köhler; Johnny Kim; Kendall Feia; Josh Bodie; Nick Johnson; Antoine Makhlouf; Manoj Monga
Journal:  Urology       Date:  2008-03-03       Impact factor: 2.649

Review 9.  Testosterone supplementation and sexual function: a meta-analysis study.

Authors:  Giovanni Corona; Andrea M Isidori; Jaques Buvat; Antonio Aversa; Giulia Rastrelli; Geoff Hackett; Vincenzo Rochira; Alessandra Sforza; Andrea Lenzi; Edoardo Mannucci; Mario Maggi
Journal:  J Sex Med       Date:  2014-04-04       Impact factor: 3.802

Review 10.  Testosterone and weight loss: the evidence.

Authors:  Abdulmaged M Traish
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

View more
  5 in total

Review 1.  Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?

Authors:  Wesley Baas; Tobias S Köhler
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

2.  Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study.

Authors:  Naomi Boxall; Dimitri Bennett; Matthias Hunger; Paul Dolin; Paula L Thompson
Journal:  BMJ Open Diabetes Res Care       Date:  2016-12-12

Review 3.  Testosterone replacement therapy and voiding dysfunction.

Authors:  Wesley Baas; Tobias S Köhler
Journal:  Transl Androl Urol       Date:  2016-12

4.  Crosstalk between apoptosis and autophagy in prostate epithelial cells under androgen deprivation.

Authors:  Rong-Fu Liu; Jian Li; Jie Zhang; Pei-De Bai; Yu-Feng Yang; Wei Li; Zhun Wu; Jia-Xin Zheng
Journal:  Exp Ther Med       Date:  2018-01-09       Impact factor: 2.447

5.  Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats.

Authors:  Rong-Fu Liu; Guo Fu; Jian Li; Yu-Feng Yang; Xue-Gang Wang; Pei-De Bai; Yue-Dong Chen
Journal:  Exp Ther Med       Date:  2018-01-19       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.